Wednesday, June 10, 2026

Intelligence Β· INN directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed 4,797
Companies 1,769
Pipeline programs 20,548

Quick answer

NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Showing page 118 of 200 Β· By data quality, then INN

  1. belantamab mafodotin

    BLENREP

    EMA: approved

    L01FX15
  2. belumosudil

    REZUROCK

    EMA: approved

    L04AA48
  3. betaine anhydrous

    AMVERSIO

    EMA: approved

    A16AA06
  4. betibeglogene autotemcel

    ZYNTEGLO

    EMA: withdrawn

    B06A
  5. bictegravir

    BIKTARVY

    EMA: approved

    J05AR20
  6. bifikafusp alfa

    NIDLEGY

    EMA: application withdrawn

    L01XY
  7. bimekizumab

    BIMZELX

    EMA: approved

    L04AC
  8. birch bark extract

    FILSUVEZ

    EMA: approved

    D03AX13
  9. blarcamesine

    BLARCAMESINE ANAVEX

    EMA: application withdrawn

    N06D
  10. bosentan monohydrate

    STAYVEER

    EMA: approved

    C02KX01
  11. bosutinib

    BOSULIF

    EMA: approved Β· NMPA: clinical trials

    L01EA04
  12. botulinum toxin type a

    BOTOX AbbVie

    EMA: approved Β· TGA: approved Β· PMDA: approved

    M03AX01
  13. botulinum toxin type b

    NEUROBLOC

    FDA: approved Β· EMA: withdrawn

    M03AX01
  14. brexucabtagene autoleucel

    TECARTUS

    EMA: approved

    L01X
  15. briakinumab

    OZESPA

    EMA: application withdrawn

    L04AC09
  16. brimonidine

    ALPHAGAN AbbVie

    EMA: approved Β· TGA: approved

    D11AX21
  17. brolucizumab

    BEOVU Novartis Pharmaceuticals

    EMA: approved Β· TGA: approved

    S01
  18. bromfenac

    YELLOX

    EMA: approved Β· NMPA: clinical trials

    S01BC11
  19. bulevirtide

    HEPCLUDEX

    EMA: approved

    J05A
  20. burosumab

    CRYSVITA KYOWA KIRIN AUSTRALIA PTY LTD

    EMA: approved Β· TGA: approved Β· PMDA: approved

    M05BX05
  21. camizestrant

    ETCAMAH

    EMA: unknown

    L02BA05
  22. caplacizumab

    CABLIVI

    EMA: approved Β· PMDA: approved

    B01A
  23. capmatinib

    TABRECTA

    EMA: approved

    L01EX17
  24. cariprazine

    REAGILA

    EMA: approved Β· TGA: approved Β· NMPA: clinical trials

    N05AX15

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles β€” INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page β€” it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.